OncoMatch/Clinical Trials/NCT05623267
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
Is NCT05623267 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Sugemalimab for limited stage small cell lung cancer.
Treatment: Sugemalimab — The purpose of this study was to evaluate the efficacy of sugemalimab consolidation therapy versus placebo in patients with LS-SCLC who had not progressed following Concurrent or Sequential Chemoradiotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage I, II, III (AJCC 8th Edition Cancer Staging)
Limited-stage SCLC (Stage I-III, by AJCC 8th Edition Cancer Staging), and can be safely treated with definitive radiation doses
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy (etoposide, carboplatin, cisplatin) — concurrent or sequential with radiotherapy during the first two cycles of chemotherapy
Completion of 4 cycles of chemotherapy (etoposide + carboplatin/cisplatin) concurrent or sequential with radiotherapy during the first two cycles of chemotherapy
Must have received: radiation therapy — concurrent or sequential with chemotherapy
concurrent or sequential with radiotherapy during the first two cycles of chemotherapy
Cannot have received: systemic anti-tumor therapy for SCLC
Exception: chemoradiotherapy as specified in inclusion
Previously received systemic anti-tumor therapy for SCLC
Cannot have received: immune checkpoint inhibitor
anti-tumor therapy with immune checkpoint inhibitors
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify